Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study Meeting Abstract

  

Authors:	Hodi, F. S.; Postow, M. A.; Chesney, J. A.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; Shaheen, M. F.; Ernstoff, M. S.; Minor, D. R.; Salama, A.; Taylor, M. H.; Ott, P. A.; Horak, C. E.; Gagnier, P.; Wolchok, J. D.
Abstract Title:	Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036901914
PROVIDER:	wos
DOI:	10.1200/jco.2015.33.15_suppl.9004
Notes:	Meeting Abstract: 9004 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80454